These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28279752)

  • 1. Novel spiroimidazopyridine derivative SAK3 improves methimazole-induced cognitive deficits in mice.
    Noreen H; Yabuki Y; Fukunaga K
    Neurochem Int; 2017 Sep; 108():91-99. PubMed ID: 28279752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Treatment with T-Type Calcium Channel Enhancer SAK3 Reduces Cognitive Impairments Caused by Methimazole-Induced Hypothyroidism Via Activation of Cholinergic Signaling.
    Husain N; Yabuki Y; Shinoda Y; Fukunaga K
    Pharmacology; 2018; 101(5-6):309-321. PubMed ID: 29597200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca
    Yabuki Y; Matsuo K; Izumi H; Haga H; Yoshida T; Wakamori M; Kakei A; Sakimura K; Fukuda T; Fukunaga K
    Neuropharmacology; 2017 May; 117():1-13. PubMed ID: 28093211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The T-type calcium channel enhancer SAK3 inhibits neuronal death following transient brain ischemia via nicotinic acetylcholine receptor stimulation.
    Yabuki Y; Jing X; Fukunaga K
    Neurochem Int; 2017 Sep; 108():272-281. PubMed ID: 28457878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-type calcium channel enhancer SAK3 produces anti-depressant-like effects by promoting adult hippocampal neurogenesis in olfactory bulbectomized mice.
    Xu J; Yabuki Y; Yu M; Fukunaga K
    J Pharmacol Sci; 2018 Aug; 137(4):333-341. PubMed ID: 30196018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Administration of the T-Type Calcium Channel Enhancer SAK3 Reduces Oxidative Stress and Improves Cognition in Olfactory Bulbectomized Mice.
    Yuan D; Cheng A; Kawahata I; Izumi H; Xu J; Fukunaga K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice.
    Izumi H; Shinoda Y; Saito T; Saido TC; Sato K; Yabuki Y; Matsumoto Y; Kanemitsu Y; Tomioka Y; Abolhassani N; Nakabeppu Y; Fukunaga K
    Neuroscience; 2018 May; 377():87-97. PubMed ID: 29510211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAK3 Administration Improves Spine Abnormalities and Cognitive Deficits in App
    Izumi H; Kawahata I; Shinoda Y; Helmstetter FJ; Fukunaga K
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32481611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-type Ca
    Degawa T; Kawahata I; Izumi H; Shinoda Y; Fukunaga K
    J Pharmacol Sci; 2021 May; 146(1):1-9. PubMed ID: 33858649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-type calcium channel enhancer SAK3 promotes dopamine and serotonin releases in the hippocampus in naive and amyloid precursor protein knock-in mice.
    Wang S; Yabuki Y; Matsuo K; Xu J; Izumi H; Sakimura K; Saito T; Saido TC; Fukunaga K
    PLoS One; 2018; 13(12):e0206986. PubMed ID: 30571684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Type Ca
    Xu J; Kawahata I; Izumi H; Fukunaga K
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat.
    Yamaguchi Y; Miyashita H; Tsunekawa H; Mouri A; Kim HC; Saito K; Matsuno T; Kawashima S; Nabeshima T
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1079-87. PubMed ID: 16474004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome.
    Janakiraman U; Dhanalakshmi C; Yu J; Moutal A; Boinon L; Fukunaga K; Khanna R; Nelson MA
    Neurobiol Dis; 2020 Sep; 143():105006. PubMed ID: 32622085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism.
    Momotani N; Noh JY; Ishikawa N; Ito K
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3633-6. PubMed ID: 9360518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats.
    Virdis A; Colucci R; Fornai M; Polini A; Daghini E; Duranti E; Ghisu N; Versari D; Dardano A; Blandizzi C; Taddei S; Del Tacca M; Monzani F
    Endocrinology; 2009 Feb; 150(2):1033-42. PubMed ID: 18927216
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.